# Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

> **NCT07270991** · PHASE3 · RECRUITING · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 324 (estimated)

## Conditions studied

- Metastatic Oesogastric Adenocarcinoma

## Interventions

- **DRUG:** trifluridine/tipiracil
- **DRUG:** fruquintinib

## Key facts

- **NCT ID:** NCT07270991
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2030-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07270991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07270991, "Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07270991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*